Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway

Fig. 3

Decitabine significantly restores CDX2 expression in CDX2-negative CRC cell lines. a Upper panel: qPCR analysis of CDX2-negative COLO205 and SW620 cells treated with increasing concentrations of the DNMTi decitabine (1.25 μM, 2.5 μM, 5 μM) for 48 h. Data were normalized to the HMBS housekeeping gene and are shown as n-fold regulation compared with DMSO-treated cells. MWU: ***p < 0.001, (n = 4) Lower panel: CDX2 Western blot analysis of cells treated as above. Total protein is shown as a loading control. b Immunohistochemistry (IHC) analysis of COLO205 and SW620 cells treated with 5 μM decitabine for 48 h. Quantification of CDX2 expression was done using the image analysis software QuPath

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us